» Articles » PMID: 15569105

Systematic Review: is Ingestion of Paracetamol or Non-steroidal Anti-inflammatory Drugs Associated with Exacerbations of Inflammatory Bowel Disease?

Overview
Date 2004 Dec 1
PMID 15569105
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To examine the published evidence on the association between paracetamol or non-steroidal anti-inflammatory drugs and relapse in inflammatory bowel disease.

Methods: Medline searches were performed till June 2004 and Embase till April 2003. Abstracts published in Gut and Gastroenterology from 1999 to 2004 were hand-searched. Twenty-nine relevant abstracts and papers were identified.

Results: Twenty-two patients with relapse of inflammatory bowel disease following exposure to non-steroidal anti-inflammatory drugs have been described in case-reports. Four patients were re-exposed to non-steroidal anti-inflammatory drugs and relapsed again. Two had relapsed after taking a cyclo-oxygenase 2 inhibitor. One study described increased inflammatory activity and clinical relapse in some patients after challenge with naproxen or nabumetone. Fifteen epidemiological studies were identified. All had small sample sizes and many had methodological problems. Six studies found evidence for an association between non-steroidal anti-inflammatory drug use and relapse of inflammatory bowel disease, but the association was significant in only two. Three studies suggested a relationship between paracetamol use and exacerbations of inflammatory bowel disease.

Conclusions: Non-steroidal anti-inflammatory drugs may precipitate a relapse in some patients with inflammatory bowel disease. This may be an idiosyncratic reaction. The published evidence does not support the view that non-steroidal anti-inflammatory drugs are important in inducing relapse of inflammatory bowel disease. There is weak evidence that paracetamol may be more important.

Citing Articles

Elevated risk of adverse effects from foodborne contaminants and drugs in inflammatory bowel disease: a review.

Walraven T, Busch M, Wang J, Donkers J, Duijvestein M, van de Steeg E Arch Toxicol. 2024; 98(11):3519-3541.

PMID: 39249550 PMC: 11489187. DOI: 10.1007/s00204-024-03844-w.


Efficacy of Ustekinumab Against Spondyloarthritis Associated with Crohn's Disease: A Case Report and Review of the Literature.

Matsumoto S, Matsumoto K, Takaya H, Otake H, Mashima H Open Access Rheumatol. 2020; 12:133-137.

PMID: 32821180 PMC: 7422905. DOI: 10.2147/OARRR.S263259.


Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation.

Moninuola O, Milligan W, Lochhead P, Khalili H Aliment Pharmacol Ther. 2018; 47(11):1428-1439.

PMID: 29620794 PMC: 5992031. DOI: 10.1111/apt.14606.


American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Ward M, Deodhar A, Akl E, Lui A, Ermann J, Gensler L Arthritis Rheumatol. 2015; 68(2):282-98.

PMID: 26401991 PMC: 5123840. DOI: 10.1002/art.39298.


American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Ward M, Deodhar A, Akl E, Lui A, Ermann J, Gensler L Arthritis Care Res (Hoboken). 2015; 68(2):151-66.

PMID: 26401907 PMC: 5123844. DOI: 10.1002/acr.22708.